The impact of invasive respiratory support on the development of postoperative atrial fibrillation following cardiac surgery.


Journal

Journal of clinical anesthesia
ISSN: 1873-4529
Titre abrégé: J Clin Anesth
Pays: United States
ID NLM: 8812166

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 11 02 2021
revised: 31 03 2021
accepted: 01 04 2021
pubmed: 30 4 2021
medline: 3 7 2021
entrez: 29 4 2021
Statut: ppublish

Résumé

Postoperative atrial fibrillation (POAF) is a frequent complication after cardiac valve- or coronary artery bypass (CABG) surgery and is associated with increased mortality. While it is known that prolonged postoperative invasive ventilation triggers POAF, the impact of ventilatory settings on POAF development has not been studied yet. Prospective observational study. Postoperative Intensive Care Unit. Patients having undergone elective CABG and/or cardiac valve surgery. Screening for the development of POAF. Patients' clinical data and postoperative ventilatory settings (driving pressure, controlled pressure above positive endexpiratory pressure (PEEP), respiration rate, and FiO2) were investigated to elucidate their impact on POAF. Out of 441 enrolled individuals, a total of 192 participants developed POAF (43.5%). We observed that POAF patients received a higher peak driving pressure, and a higher peak respiration rate than non-POAF individuals. Within the multivariate regression model, plateau pressure (adjusted OR 1.199 [1.038-1.661], p = 0.019), driving pressure (adjusted OR 1.244 [1.103-1.713], p = 0.021), and peak respiration rate (adjusted OR 1.206 [1.005-1.601], p = 0.040) proved to be independently associated with the development of POAF. CART analysis revealed a cut-off of ≥17.5 cmH The ventilatory settings of plateau pressure, driving pressure, and respiration rate after cardiac surgery influence POAF occurrence probability. Optimized postoperative care such as lung-protective ventilation and increased awareness towards postoperative ventilatory efforts should be considered to prevent POAF development and poor patient outcome.

Identifiants

pubmed: 33915411
pii: S0952-8180(21)00148-3
doi: 10.1016/j.jclinane.2021.110309
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

110309

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Sebastian Schnaubelt (S)

Department of Emergency Medicine, Medical University of Vienna, Austria.

Alexander Stajic (A)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Lorenz Koller (L)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Felix Hofer (F)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Niema Kazem (N)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Andreas Hammer (A)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Martin Andreas (M)

Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Austria.

Günther Laufer (G)

Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Austria.

Barbara Steinlechner (B)

Division of Cardiothoracic and Vascular Anesthesia, Department of Anesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Austria.

Bernhard Richter (B)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Alexander Niessner (A)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria. Electronic address: alexander.niessner@meduniwien.ac.

Patrick Sulzgruber (P)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH